Searchable abstracts of presentations at key conferences in endocrinology

ea0047oc45 | Innovative Theranostics | Theranostics2016

Glioma tumors grade II/III – local alpha emiters targeted therapy with 213Bi-DOTA-substance P

Krolicki Leszek LK , Morgenstern Alfred AM , Kunikowska Jolanta JK , Koziara Henryk HK , Bartosz Krolicki BK , Jakucinski Maciej MJ , Pawlak Dariusz DP , Apostolidis Constantinos CA , Bruchertseifer Frank FB

Gliomas are a highly heterogeneous group of brain tumours that are refractory to treatment, and highly invasive. The treatment and prognosis depend upon the tumor grade. Treatment of Grade II/III gliomas typically consists of maximal safe resection, followed by external beam radiation therapy. Although less aggressive than GBM, mortality is high with a 5-year survival rate of only 25.9%. Glioma tumors has been demonstrated NK-1 receptor system and substance P can be used as a ...

ea0035p1035 | Thyroid (non-cancer) | ECE2014

Results of preventive radioiodine therapy in euthyroid patients with history of hyperthyroidism prior to administration of amiodarone with permanent atrial fibrillation (preliminary study)

Czarnywojtek Agata , Wolinski Kosma , Gut Pawel , Czepczynski Rafal , Plazinska Maria Teresa , Kunikowska Jolanta , Kobylecka Malgorzata , Miechowicz Izabela , Krolicki Leszek , Ruchala Marek

Introduction: Radioiodine (RAI) therapy is a standard procedure in therapy of hyperthyroidism. However, the use of RAI in euthyroid patients requiring chronic administration of amiodarone (AM), in a case of lacking efficacy of other antiarrhythmic drugs might be controversial.Objective: The aim of the study was to assess the safety and efficacy of an AM therapy prior to treatment with radioiodine therapy in euthyroid patients with permanent atrial fibril...

ea0020p203 | Endocrine tumours and neoplasia | ECE2009

Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours (NETs)

Sowa-Staszczak Anna , Hubalewska-Dydejczyk Alicja , Kunikowska Jolanta , Krolicki Leszek , Mikolajczak Renata , Pawlak Dariusz , Gilis-Januszewska Aleksandra , Trofimiuk Malgorzata , Stefanska Agnieszka

Therapy with labeled somatostatin analogues is the modern approach to patients with disseminated or unresectable NETs expressing somatostatin receptors (SSTR). Octreotate is the somatostatin analogue with high affinity to SSTR type 2, most commonly present in NETs. The aim of the study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of 90Y labelled Tyr3-octreotate, (90Y-DOTATATE) in NETs....

ea0014p131 | (1) | ECE2007

Results 90Y-DOTATATE therapy in patients with neuroendocrine tumours (NETs) - own experience

Kunikowska Jolanta , Hubalewska-Dydejczyk Alicja , Sowa-Staszczak Anna , Krolicki Leszek , Ochman Pawel , Mikolajczak Renata , Pawlak Dariusz , Kobylecka Malgorzata , Maczewska Joanna , Huszno Bohdan

In the 1980 s the discovery of expression of somatostatin receptors on NET cells made the use of somatostatin analogues in diagnosis and therapy possible.The aim: Of the study was to assess response of targeted radio-nuclide therapy with radio-labelled somatostatin analogue 90Y-[DOTA0,D-Phe1,Tyr3]-octreotate (DOTATATE) in treatment of disseminated NETs.Material and methods: 12 patients (a...